EHJ - Cardiovascular Pharmacotherapy
Focusing on clinical cardiovascular pharmacology
Showing 24 of 835 results
ESC Journals
A farewell to professor Stefan Agewall from the ESC Working Group on Cardiovascular Pharmacotherapy
27 February 2026
ESC Journals
Correction to: Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee
4 February 2026
ESC Journals
ESC Journals
Different aspects of myocardial intervention and pharmacological treatment
2 February 2026
ESC Journals
Cardiovascular adverse effects of common non-oncologic medications: from mechanisms to clinical management
2 February 2026
ESC Journals
Aspirin may take a back row seat for non-ST-segment elevation acute coronary syndrome after percutaneous coronary intervention
29 January 2026
ESC Journals
Effect of beta blockers in acute and chronic coronary syndromes without reduced ejection fraction: a landmark analysis from the REBOOT trial
22 January 2026
ESC Journals
Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system
22 January 2026
ESC Journals
Withdrawing heart failure therapy after AF rhythm control: promise, caution, and perspective
20 January 2026
ESC Journals
SGLT2 inhibitors are associated with improved long-term survival in Takotsubo syndrome: insights from large-scale real-world data
19 January 2026
ESC Journals
Cardiovascular safety of 5α-reductase inhibitors in people with benign prostatic hyperplasia and type 2 diabetes: a propensity score-matched analysis
17 January 2026
ESC Journals
The role of aetiology in determining anticoagulation effectiveness for the treatment of left ventricular thrombus
31 December 2025
ESC Journals
Real-world evidence of finerenone in Type 2 diabetes: addressing confounding and follow-up duration
16 December 2025
ESC Journals
Finerenone for diabetic hearts: a critical appraisal of MACE benefits and the research road ahead
16 December 2025
ESC Journals
ESC Journals
Digitoxin in heart failure: a statistical signal, or just noise? A reappraisal of the DIGIT-HF trial
16 December 2025
ESC Journals
OCEAN trial: rethinking long-term anticoagulation after atrial fibrillation ablation
12 December 2025
ESC Journals
Intracoronary adjunctive therapies for ST-elevation myocardial infarction: a network meta-analysis of trials
9 December 2025
ESC Journals
Antithrombotic strategies and DOAC dosing following left atrial appendage occlusion: a network meta-analysis
25 November 2025
ESC Journals
VESALIUS keeps revolutionizing medicine: the case of evolocumab in primary prevention
21 November 2025
ESC Journals
Reply to ‘Sacubitril/valsartan in heart failure: a critical look at dementia risk and future study pathways’
16 November 2025
ESC Journals
Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort study
4 November 2025
ESC Journals
ESC Journals
Sacubitril/valsartan in heart failure: a critical look at dementia risk and future study pathways
31 October 2025
